Advanced Search

 

Study ID Status Title Patient Level Data
EGF108991 Completed A Phase I/II Study of Lapatinib in Combination with Oxaliplatin and Capecitabine in Subjects with Advanced or Metastatic Colorectal Cancer
EGF109462 Completed A single-arm, two-stage Phase II study of Lapatinib and Pemetrexed in the second line treatment of advanced or metastatic Non-Small Cell Lung Cancer
EGF109491 Relinquished An Open-Label Multicenter study Administering Lapatinib and Capecitabine in Women with Advanced or MEtastatic Breast Cancer
EGF110557 Completed An Open-Label, Two-Part, Single Sequence Study to Examine the Effects of Lapatinib on the Pharmacokinetics of Orally Administered Digoxin in Subjects with Metastatic ErbB2 Positive Breast Cancer
EGF110656 Relinquished A Phase III Study for ErbB2 Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Junction Adenocarcinoma treated with Capecitabine plus Oxaliplatin with or without Lapatinib
EGF19060 Completed An Open Label, Phase 1b Rollover Study to Assess the Long-Term Safety Profile of Lapatinib (GW572016) in Cancer Patients.
EGF20001 Completed A parallel-arm, multi-center, open-label randomized phase II study of orally administered GW572016 as single-agentsecond-line treatment of patients with locally advanced or metastatic renal cell carcinoma
EGF20003 Completed A single-arm, multi-centre, open-label phase II study of orally administered GW572016 as single-agent second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma of the urothelial tract
EGF20004 Completed An Open-Label, Multicenter, Phase II Study of Oral Lapatinib (GW572016) as Single Agent, Second-Line Therapy in Subjects with Metastatic Colorectal Cancer Who Have Progressed on First-Line Therapy with 5-Fluorouracil in Combination with Irinotecan or Oxaliplatin
EGF20008 Completed An Open-Label, Multicenter, Single Arm Phase II Study of Oral GW572016 as Single Agent Therapy in Subjects with Advanced or Metastatic Breast Cancer Who Have Progressed While Receiving HERCEPTIN-Containing Regimens
EGF20009 Completed A Phase II, Open-Label, Randomized, Parallel-Group Multicenter Trial Comparing Two Schedules of GW572016 as First-Line Monotherapy in Patients with Advanced or Metastatic Breast Cancer
EGF20014 Terminated A Phase 2 Multicenter Trial Comparing Two Schedules of GW572016 as First or Second Line Monotherapy in Subjects with Advanced or Metastatic Non-Small Cell Lung Cancer with either Bronchioloalveolar Carcinoma or No Smoking History
EGF30001 Relinquished A Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Phase III Study of Oral GW572016 in Combination with Paclitaxel in Subjects Previously Untreated or Advanced or Metastatic Breast Cancer
EGF30008 Relinquished A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study Comparing GW572016 and Letrozole versus Letrozole in Subjects with Estrogen/Progesterone Receptor-Positive Advanced or Metastatic Breast Cancer
EL110002 Completed A single-centre, randomised, double-blind, double-dummy, placebo-controlled, 3-period crossover study to evaluate the effect of pre-treatment with repeat doses of a new chemical entity (NCE) on the allergen-induced late asthmatic response in subjects with mild to moderate asthma, using…
EL110003 Completed A single centre, randomised, double-blind, placebo-controlled, repeat dose, 4-period cross-over study to evaluate the safety, pharmacokinetics and pharmacodynamics (including the effect on QTc) of a single dose of nebulised salbutamol (5 mg), following repeat-dose administration of a new chemica ...
EL110025 Completed A single-centre, randomised, double-blind, double-dummy, 3-period cross-over study to evaluate the effect of two single doses of inhaled NCE on the subsequent bronchodilator effect of a sub-therapeutic dose of salbutamol (10 mg administered by dosimeter) in patients with moderate asthma.
ELR100710 Completed A Study to Validate Key Therapeutic Targets and Biomarkers during Allergen Exposure in Subjects with Allergic Rhinitis
EMD10007 Completed An Open-Label, Non-Randomised, Pharmacokinetic, Metabolic Disposition and Safety study of a 3 Day Continuous Infusion of GR270773 in Healthy Subjects and Subjects with Hepatic Impairment.
EMD20001 Completed A Prospective, Randomized, Double-blind, Placebo Controlled, Dose Ranging, Multi-Center Study of the Safety and Efficacy of Three Days Continuous Intravenous Infusion of GR270773 in the Treatment of Suspected or Confirmed Gram-negative Severe Sepsis in Adults
EMD20001_1 Completed Long-Term Mortality and Health Outcomes Results from a Prospective, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Multicenter Study of the Safety and Efficacy of Three Days of Continuous IntravenousInfusion of GR270773 in the Treatment of Suspected or Confirmed Gram-Negative Severe ...
EPI40007 Completed The Antiretroviral Pregnancy Registry (APR, Registry)
EPI40048 Completed GlaxoSmithKline International Lamotrigine Pregnancy Registry
EPI40050 Completed The Sumatriptan and Naratriptan Pregnancy Registry
EPI40050_1 Completed The Sumatriptan and Naratriptan Pregnancy Registry

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.